Three cases of schizophrenia resistant to conventional treatment are described. Each responded to treatment with remoxipride, a recently introduced neuroleptic that interacts selectively with dopamine D2 and opiate sigma receptors. Remoxipride may prove to be a useful agent in the treatment of 'neuroleptic-resistant' schizophrenia.